FMC Corp: Form 10-Q for the period ended Mar 31, 2020
Filed with the SEC on May 6, 2020 and accepted by EDGAR at May 6, 2020, 13:25 ET.
Management's discussion and analysis
As filed, 63,723 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.
Item 2 of this report contains certain forward-looking statements that are based on our current views and assumptions regarding future events, future business conditions and the outlook for our company based on currently available information.
Whenever possible, we have identified these forward-looking statements by such words or phrases as "will likely result," "is confident that," "expect," "expects," "should," "could," "may," "will continue to," "believe," "believes," "anticipates," "predicts," "forecasts," "estimates," "projects," "potential," "intends" or similar expressions identifying "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including the negative of those words or phrases. Such forward-looking statements are based on our current views and assumptions regarding future events, future business conditions and the outlook for the company based on currently available information. The forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any results, levels of activity, performance or achievements expressed or implied by any forward-looking statement. Currently, one of the most significant factors is the potential adverse effect of the current COVID-19 pandemic on our financial condition, results of operations, cash flows and performance, which is substantially influenced by the potential adverse effect of the pandemic on our customers and suppliers and the global economy and financial markets. The extent to which COVID-19 impacts us will depend on future developments, which are highly uncertain and cannot be predicted with confidence, including the scope, severity and duration of the pandemic, the actions taken to contain the pandemic or mitigate its impact, and the direct and indirect economic effects of the pandemic and containment measures, among others. Additional factors include, among other things, the risk factors included in Part II, Item 1A of our Annual Report on Form 10-K for the year ended December 31, 2019 (the "2019 Form 10-K"), and the section captioned "Forward-Looking Information" in Part II of the 2019 Form 10-K, the risk factor in Item 1A in this Form 10-Q, and to similar risk factors and cautionary statements in all other reports and forms filed with the Securities and Exchange Commission ("SEC"). Moreover, investors are cautioned to interpret many of these factors as being heightened as a result of the ongoing and numerous adverse impacts of COVID-19. We wish to caution readers not to place undue reliance on any such forward-looking statements, which speak only as of the date made.
We specifically decline to undertake any obligation to publicly revise any forward-looking statements that have been made to reflect events or circumstances after the date of such statements or to reflect the occurrence of anticipated or unanticipated events.
APPLICATION OF CRITICAL ACCOUNTING POLICIES
Our consolidated financial statements are prepared in conformity with U.S. generally accepted accounting principles. The preparation of our financial statements requires management to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues and expenses. We have described our accounting policies in Note 1 to our consolidated financial statements included in our 2019 Form 10-K. We have reviewed these accounting policies, identifying those that we believe to be critical to the preparation and understanding of our consolidated financial statements. We have reviewed these critical accounting policies with the Audit Committee of our Board of Directors. Critical accounting policies are central to our presentation of results of operations and financial condition and require management to make estimates and judgments on certain matters. We base our estimates and judgments on historical experience, current conditions and other reasonable factors.
The following is a list of those accounting policies that we have deemed most critical to the presentation and understanding of our results of operations and financial condition. See the "Critical Accounting Policies" section in our 2019 Form 10-K for a detailed description of these policies and their potential effects on our results of operations and financial condition.
- Revenue recognition and trade receivables
- Environmental obligations and related recoveries
- Impairment and valuation of long-lived assets and indefinite-lived assets
- Pensions and other postretirement benefits
- Income taxes
On January 1, 2020, ASU No. 2016-13, Financial Instruments – Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments, became effective. See Note 2 for more information. Our revenue recognition and trade receivables critical accounting policy has been updated in order to comply with the accounting standard update. The updated policy refines the process of estimating the allowance for doubtful accounts receivables by incorporating past events, current business conditions, and reasonable and supportable forecasts of future economic conditions that affect the collectability of the reported amounts.
RECENTLY ISSUED AND ADOPTED ACCOUNTING PRONOUNCEMENTS AND REGULATORY ITEMS
See Note 2 to the condensed consolidated financial statements included in this Form 10-Q for a discussion of recently adopted accounting guidance and other new accounting guidance.
OVERVIEW
We are an agricultural sciences company, providing innovative solutions to growers around the world with a robust product portfolio fueled by a market-driven discovery and development pipeline in crop protection, plant health, and professional pest and turf management. We operate in a single distinct business segment and develop, market and sell all three major classes of crop protection chemicals: insecticides, herbicides and fungicides. These products are used in agriculture to enhance crop yield and quality by controlling a broad spectrum of insects, weeds and disease, as well as in non-agricultural markets for pest control. This powerful combination of advanced technologies includes leading insect control products based on Rynaxypyr® and Cyazypyr® active ingredients; Authority®, Boral®, Centium®, Command® and Gamit® branded herbicides; Talstar® and Hero® branded insecticides; and flutriafol-based fungicides. The FMC portfolio also includes biologicals such as Quartzo® and Presence® bionematicides.
COVID-19 Pandemic
Given the COVID-19 pandemic, many countries, including the United States, subsequently imposed restrictions on both travel and business closures in an effort to mitigate the spread of COVID-19. As an agricultural sciences company, we are considered an "essential" industry in the countries in which we operate and have avoided significant plant closures and all our facilities are operational. While we have maintained business continuity and sustained our operations, we do not yet know the full extent of the disruptions on either our business and operations or the global economy nor the duration of the pandemic and its adverse effects.
We were successfully able to mitigate the impact of the pandemic in the first quarter of 2020. However, we are conscious of the potential downside risks in the rest of the year and expect to see disruption caused by COVID-19 in our supply chain, logistics, and pockets of demand, as well as the food chain going forward. As a result, we have widened our guidance ranges to incorporate more risk to the downside of prior guidance ranges. We have also temporarily implemented specific cost saving measures. Additionally, out of an abundance of caution, we drew down $500 million on our revolving credit facility in March to ensure we had sufficient liquidity regardless of near-term volatility in commercial paper markets. Separately, we amended our debt covenants with our banks to provide significant headroom above any of the COVID-19 related scenarios assessed by the company. We will continue to monitor this situation on an ongoing basis and assess the impacts on our business.
First Quarter 2020 Highlights
The following items are the more significant developments or financial highlights in our business during the three months ended March 31, 2020:
- Revenue of $1,250.0 million for the three months ended March 31, 2020 increased $57.9 million or approximately 5 percent versus the same period last year. A more detailed review of revenue is discussed under the section titled "Results of Operations". On a regional basis, sales in North America increased by approximately 3 percent, sales in Latin America increased approximately 26 percent, sales in Europe, Middle East and Africa increased by approximately 1 percent, and sales in Asia decreased approximately 3 percent. The increase was mostly driven by growth in Latin America, North America and EMEA, as well as price increases across all regions, partially offset by foreign exchange headwinds. Excluding foreign currency impacts, revenue increased 9 percent during the quarter.
- Our gross margin of $561.5 million increased versus the prior year quarter by $16.8 million mostly due to higher volumes and pricing. Gross margin percent of approximately 45 percent slightly decreased compared to approximately 46 percent in the prior year period.
- Selling, general and administrative expenses increased from $183.9 million to $189.4 million. Selling, general and administrative expenses, excluding transaction-related charges, of $176.4 million increased approximately 5 percent compared to the prior year period.
- Research and development expenses of $67.3 million decreased $3.9 million or approximately 5 percent. We maintain our commitment to invest resources to discover new active ingredients and formulations that support resistance management and sustainable agriculture.
- We have implemented temporary cost-saving measures and are eliminating or delaying all non-essential expenditures to offset projected headwinds from the effects of the COVID-19 pandemic. These efforts are primarily focused on selling, general and administrative expenses and research and development expenses. We are not cancelling any research and development projects, but we are phasing some differently to allow for lower costs in the current year without fundamentally impacting long-term timelines.
- Net income (loss) attributable to FMC stockholders decreased from $215.7 million to $206.2 million which represents a decrease of $9.5 million, or approximately 4 percent. Adjusted after-tax earnings from continuing operations
attributable to FMC stockholders of $239.6 million increased compared to the prior year amount of $229.3 million. See the disclosure of our Adjusted Earnings Non-GAAP financial measurement below, under the section titled "Results of Operations".
Other Highlights
In May 2020, FMC entered into a binding offer with Isagro S.p.A ("Isagro") whereby FMC will acquire Isagro’s Fluindapyr active ingredient assets for approximately $60 million. Fluindapyr has been jointly developed by FMC and Isagro under a 2012 research and development collaboration agreement. The transaction will provide FMC with full global rights to Fluindapyr active ingredient, including key U.S., European, Asian, and Latin American fungicide markets. The transaction, expected to close by the end of the third quarter 2020, will transfer to FMC all intellectual property, know-how, registrations, product formulations and other global assets of the proprietary broad-spectrum fungicide molecule.
2020 Outlook Update
As a result of the uncertainty surrounding the COVID-19 pandemic, our current 2020 expectation for the overall global crop protection market growth is that it will be flat, on a U.S. dollar basis, down from the low-single digit growth we expected. We expect both the North America and EMEA markets to be up low-single digits while Asia and LATAM is expected to be down low-single digits, primarily driven by negative foreign exchange impacts.
We are widening our guidance ranges to incorporate more risk to the downside of prior guidance ranges. We now expect 2020 revenue will be in the range of approximately $4.65 billion to $4.85 billion, up approximately 3 percent at the midpoint versus 2019 or approximately 8 percent excluding the impacts of foreign currency. We also expect adjusted EBITDA(1) of $1.23 billion to $1.34 billion, which represents 5 percent growth at the midpoint versus 2019 results. 2020 adjusted earnings are expected to be in the range of $6.05 to $6.70 per diluted share(1), up 5 percent at the midpoint versus 2019. Adjusted earnings excludes the benefit of any share repurchases in 2020, which we are suspending. For cash flow outlook, refer to the liquidity and capital resources section below.
(1) Although we provide forecasts for adjusted earnings per share and adjusted EBITDA (Non-GAAP financial measures), we are not able to forecast the most directly comparable measures calculated and presented in accordance with U.S. GAAP. Certain elements of the composition of the U.S. GAAP amounts are not predictable, making it impractical for us to forecast. Such elements include, but are not limited to, restructuring, acquisition charges, and discontinued operations. As a result, no U.S. GAAP outlook is provided.
RESULTS OF OPERATIONS
Overview
The following charts provide a reconciliation of Adjusted EBITDA and Adjusted Earnings, both of which are Non-GAAP financial measures, from the most directly comparable GAAP measure. Adjusted EBITDA is provided to assist the readers of our financial statements with useful information regarding our operating results. Our operating results are presented based on how we assess operating performance and internally report financial information. For management purposes, we report operating performance based on earnings before interest, income taxes, depreciation and amortization, discontinued operations, and corporate special charges. Our Adjusted Earnings measure excludes corporate special charges, net of income taxes, discontinued operations attributable to FMC stockholders, net of income taxes, and certain Non-GAAP tax adjustments. These are excluded by us in the measure we use to evaluate business performance and determine certain performance-based compensation. These items are discussed in detail within the "Other Results of Operations" section that follows. In addition to providing useful information about our operating results to investors, we also believe that excluding the effect of corporate special charges, net of income taxes, and certain Non-GAAP tax adjustments from operating results and discontinued operations allows management and investors to compare more easily the financial performance of our underlying business from period to period. These measures should not be considered as substitutes for net income (loss) or other measures of performance or liquidity reported in accordance with U.S. GAAP.
(in Millions)
(unaudited)
| 2020 | Three Months Ended March 31, 2019 | |
|---|---|---|
| Revenue | $1,250.0 | $1,192.1 |
| Costs of sales and services | 688.5 | 647.4 |
| Gross margin | $561.5 | $544.7 |
| Selling, general and administrative expenses | 189.4 | 183.9 |
| Research and development expenses | 67.3 | 71.2 |
| Restructuring and other charges (income) | 13.4 | 7.8 |
| Total costs and expenses | $958.6 | $910.3 |
| Income from continuing operations before non-operating pension and postretirement charges (income), interest expense, net and income taxes (1) | $291.4 | $281.8 |
| Non-operating pension and postretirement charges (income) | 2.2 | 3.4 |
| Interest expense, net | 40.8 | 34.5 |
| Income (loss) from continuing operations before income taxes | $248.4 | $243.9 |
| Provision (benefit) for income taxes | 34.7 | 36.3 |
| Income (loss) from continuing operations | $213.7 | $207.6 |
| Discontinued operations, net of income taxes | (7.5) | 9.6 |
| Net income (loss) (GAAP) | $206.2 | $217.2 |
| Adjustments to arrive at Adjusted EBITDA: | ||
| Corporate special charges (income): | ||
| Restructuring and other charges (income) (3) | $13.4 | $7.8 |
| Non-operating pension and postretirement charges (income) (4) | 2.2 | 3.4 |
| Transaction-related charges (5) | 13.0 | 16.5 |
| Discontinued operations, net of income taxes | 7.5 | (9.6) |
| Interest expense, net | 40.8 | 34.5 |
| Depreciation and amortization | 39.1 | 37.3 |
| Provision (benefit) for income taxes | 34.7 | 36.3 |
| Adjusted EBITDA (Non-GAAP) (2) | $356.9 | $343.4 |
(1) Referred to as operating profit.
(2) Adjusted EBITDA is defined as operating profit excluding corporate special charges (income) and depreciation and amortization expense.
(3) See Note 10 for details of restructuring and other charges (income).
(4) Our non-operating pension and postretirement charges (income) are defined as those costs (benefits) related to interest, expected return on plan assets, amortized actuarial gains and losses and the impacts of any plan curtailments or settlements. These are excluded from our operating results and are primarily related to changes in pension plan assets and liabilities which are tied to financial market performance and we consider these costs to be outside our operational performance. We continue to include the service cost and amortization of prior service cost in our operating results noted above. These elements reflect the current year operating costs to our business for the employment benefits provided to active employees.
(5) Represents transaction costs, costs for transitional employees, other acquired employees related costs, and transactional-related costs such as legal and professional third-party fees.
(in Millions)
| DuPont Crop Protection Business Acquisition | Three Months Ended March 31, 2020 | 2019 |
|---|---|---|
| Legal and professional fees (1) | $13.0 | $16.5 |
| Total Transaction-related charges | $13.0 | $16.5 |
(1) These charges are recorded as a component of "Selling, general and administrative expense" on the condensed consolidated statements of income (loss).
ADJUSTED EARNINGS RECONCILIATION
(in Millions)
(unaudited)
| 2020 | Three Months Ended March 31, 2019 | |
|---|---|---|
| Net income (loss) attributable to FMC stockholders (GAAP) | $206.2 | $215.7 |
| Corporate special charges (income), pre-tax (1) | 28.6 | 27.7 |
| Income tax (expense) benefit on Corporate special charges (income) (2) | (4.9) | (5.7) |
| Corporate special charges (income), net of income taxes | $23.7 | $22.0 |
| Discontinued operations attributable to FMC Stockholders, net of income taxes | 7.5 | (9.6) |
| Non-GAAP tax adjustments (3) | 2.2 | 1.2 |
| Adjusted after-tax earnings from continuing operations attributable to FMC stockholders (Non-GAAP) | $239.6 | $229.3 |
(1) Represents restructuring and other charges (income), non-operating pension and postretirement charges (income), and transaction-related charges.
(2) The income tax expense (benefit) on corporate special charges (income) is determined using the applicable rates in the taxing jurisdictions in which the corporate special charge (income) occurred and includes both current and deferred income tax expense (benefit) based on the nature of the Non-GAAP performance measure.
(3) We exclude the GAAP tax provision, including discrete items, from the Non-GAAP measure of income, and instead include a Non-GAAP tax provision based upon the annual Non-GAAP effective tax rate. The GAAP tax provision includes certain discrete tax items including, but not limited to: income tax expenses or benefits that are not related to current year ongoing business operations; tax adjustments associated with fluctuations in foreign currency remeasurement of certain foreign operations; certain changes in estimates of tax matters related to prior fiscal years; and certain changes in the realizability of deferred tax assets. Management believes excluding these discrete tax items assists investors and securities analysts in understanding the tax provision and the effective tax rate related to ongoing operations thereby providing investors with useful supplemental information about FMC's operational performance.
Results of Operations
In the discussion below, all comparisons are between the periods unless otherwise noted.
Revenue
Three Months Ended March 31, 2020 vs. 2019
Revenue of $1,250.0 million increased $57.9 million, or approximately 5 percent, versus the prior year period. The increase was driven by higher volumes, which contributed approximately 7 percent to the increase, primarily in Latin America, as well as favorable pricing across all regions which impacted revenue by approximately 2 percent. Foreign currency fluctuations had an unfavorable impact on the change in revenue of approximately 4 percent. The increase in revenue was driven by strong commercial execution and demand for our products. See below for a discussion of revenue by region.
Total Revenue by Region
(in Millions)
| Three Months Ended March 31, 2020 | 2019 | |
|---|---|---|
| North America | $327.6 | $318.3 |
| Latin America | 259.2 | 206.5 |
| Europe, Middle East & Africa (EMEA) | 415.3 | 412.0 |
| Asia | 247.9 | 255.3 |
| Total Revenue | $1,250.0 | $1,192.1 |
Three Months Ended March 31, 2020 vs. 2019
North America: Revenue increased approximately 3 percent versus the prior year period due to strong demand for Rynaxypyr® insect control, fungicides, and our new pre-emergent herbicide Authority® Edge. Double digit growth in Canada was driven by continued adoption of our Authority® herbicides due to resistance concerns.
Latin America: Revenue increased approximately 26 percent versus the prior year period, or approximately 38 percent excluding foreign currency headwinds, driven by double-digit growth in Brazil, Mexico, and Argentina. Insecticides were particularly strong in Brazil, driven by cotton, sugarcane and soybeans, and herbicide growth was driven by sugarcane replanting. In Argentina, insecticide demand drove new sales, and in Mexico, fruit and vegetable exports continued to present increased opportunities for our diamide portfolio.
EMEA: Revenue increased approximately 1 percent versus the prior year period, or approximately 4 percent excluding foreign currency headwinds, primarily due to very strong demand for fungicide product launches and solid growth in herbicides for cereals. We saw growth in over 10 countries, with double-digit growth in France, UK, and Russia, and approximately 2 percent growth in overall revenue from new products in the quarter. This was partially offset by registration cancellations and product rationalizations.
Asia: Revenue decreased approximately 3 percent versus the prior year period, but remained flat excluding foreign currency headwinds, primarily driven by the impact of COVID-19 on both supply and demand in China, partially offset by double-digit growth in India and Pakistan, and organic growth in Australia as weather improved.
For 2020, full-year revenue is expected to be in the range of approximately $4.65 billion to $4.85 billion, which represents approximately 3 percent growth at the midpoint versus 2019 or approximately 8 percent excluding the impacts of foreign currency. Higher volumes are expected to contribute to the growth, with the largest volume growth expected in Asia. We expect negative foreign currency impacts due to the large shift in global currencies, but expect to offset most of the currency headwinds with price increases through the year.
Gross margin
Three Months Ended March 31, 2020 vs. 2019
Gross margin of $561.5 million increased $16.8 million, or approximately 3 percent versus the prior year period. The increase was primarily due to the higher revenues which were driven by increased volumes as well as pricing, partially offset by negative foreign currency impacts.
Gross margin percent of approximately 45 percent decreased from approximately 46 percent in the prior year period. The negative foreign currency impacts were only partially offset by higher pricing.
Selling, general and administrative expenses
Three Months Ended March 31, 2020 vs. 2019
Selling, general and administrative expenses of $189.4 million increased $5.5 million, or approximately 3 percent versus the prior year period. Selling, general and administrative expenses, excluding transaction-related charges, increased $9.0 million, or approximately 5 percent, versus the prior year period.
Research and development expenses
Three Months Ended March 31, 2020 vs. 2019
Research and development expenses of $67.3 million decreased $3.9 million, or approximately 5 percent versus the prior year period. As noted above, we are eliminating or delaying non-essential expenditures to offset effects of the COVID-19 pandemic, but we are not cancelling any projects.
Adjusted EBITDA (Non-GAAP)
Three Months Ended March 31, 2020 vs. 2019
Adjusted EBITDA of $356.9 million increased $13.5 million, or approximately 4 percent versus the prior year period. The increase was due to the strong demand which led to higher pricing across all regions and higher volumes as discussed above which contributed approximately 8 percent and 12 percent to the increase, respectively. These factors more than offset the higher costs and unfavorable foreign currency fluctuations which impacted the change in Adjusted EBITDA by approximately 2 percent and 14 percent, respectively.
For 2020, full-year Adjusted EBITDA is expected to be in the range of $1.23 billion to $1.34 billion, which represents approximately 5 percent growth at the midpoint versus 2019. We expect strong pricing and higher volumes to more than offset the negative foreign currency impacts and higher costs. Although we provide a forecast for Adjusted EBITDA, a Non-GAAP financial measure, we are not able to forecast the most directly comparable measure calculated and presented in accordance with U.S. GAAP. See Note 1 to our 2020 Outlook Update within this section of the Form 10-Q.
Other Results of Operations
Depreciation and amortization
Three Months Ended March 31, 2020 vs. 2019
Depreciation and amortization of $39.1 million increased $1.8 million, or approximately 5 percent, as compared to the prior year period of $37.3 million. The slight increase was mostly driven by the impacts of the amortization effects of the completion of various phases of our ERP implementation.
Interest expense, net
Three Months Ended March 31, 2020 vs. 2019
Interest expense, net of $40.8 million increased compared to the prior year period of $34.5 million. The increase was driven by the issuance of the Senior Notes during the third quarter of 2019 which increased interest expense by approximately $9 million and higher foreign debt balances which increased interest expense by approximately $4 million, partially offset by lower 2017 Term Loan balances and commercial paper balances.
Corporate special charges (income)
Restructuring and other charges (income)
(in Millions)
| Three Months Ended March 31, 2020 | 2019 | |
|---|---|---|
| Restructuring charges | $6.6 | $5.2 |
| Other charges (income), net | 6.8 | 2.6 |
| Total restructuring and other charges (income) | $13.4 | $7.8 |
Three Months Ended March 31, 2020 vs. 2019
Restructuring charges in 2020 of $6.6 million primarily comprised of charges associated with the integration, which is near finalization, of the DuPont Crop Protection Business. These charges include severance, accelerated depreciation on certain fixed assets, and other costs (benefits) of $7.0 million. We expect integration-related activity to end in 2020. There were other miscellaneous restructuring benefits of $0.4 million.
Restructuring and asset disposal charges in 2019 of $5.2 million primarily comprised of charges associated with the integration of the DuPont Crop Protection Business. These charges include severance, accelerated depreciation on certain fixed assets, and other costs (benefits) of $3.9 million. Additionally, charges include Corporate charges of $1.3 million.
Other charges, net in 2020 of $6.8 million primarily consists of charges related to environmental sites of $6.4 million.
Other charges, net in 2019 of $2.6 million consists of charges related to environmental sites.
Non-operating pension and postretirement charges (income)
Charges for the three months ended March 31, 2020 were $2.2 million compared to $3.4 million for the three months ended March 31, 2019.
Transaction-related charges
A detailed description of the transaction-related charges is included in Note 5 to the condensed consolidated financial statements included within this Form 10-Q.
Provision for income taxes
A significant amount of our earnings are generated by foreign subsidiaries and taxed at lower statutory rates than the United States federal statutory rate (e.g., Singapore, Hong Kong, and Switzerland). Our future effective tax rates may be materially impacted by numerous items including: a future change in the composition of earnings from foreign and domestic tax jurisdictions, as earnings in foreign jurisdictions are typically taxed at more favorable rates than the United States federal statutory rate; accounting for uncertain tax positions; business combinations; expiration of statute of limitations or settlement of tax audits; changes in valuation allowance; changes in tax rates or laws; and the potential decision to repatriate certain future foreign earnings on which United States or foreign withholding taxes have not been previously accrued.
Three Months Ended March 31, 2020 vs. 2019
Provision for income taxes for the three months ended March 31, 2020 was $34.7 million resulting in an effective tax rate of 14.0 percent. Provision for income taxes for the three months ended March 31, 2019 was $36.3 million resulting in an effective tax rate of 14.9 percent.
(in Millions)
| Three Months Ended March 31, 2020 Income (Expense) | Tax Provision (Benefit) | Effective Tax Rate | 2019 Income (Expense) | Tax Provision (Benefit) | Effective Tax Rate | |
|---|---|---|---|---|---|---|
| GAAP - Continuing operations | $248.4 | $34.7 | 14.0% | $243.9 | $36.3 | 14.9% |
| Corporate special charges (income) | 28.6 | 4.9 | 27.7 | 5.7 | ||
| Tax adjustments (1) | (2.2) | (1.2) | ||||
| Non-GAAP - Continuing operations | $277.0 | $37.4 | 13.5% | $271.6 | $40.8 | 15.0% |
(1) Refer to Note 3 of the Adjusted Earnings Reconciliation table within this section of this Form 10-Q for an explanation of tax adjustments.
The primary drivers for the decrease in the year-to-date effective tax rate for 2020 compared to 2019 are shown in the table above. The remaining changes were primarily due to the impact of geographic mix of earnings among our global subsidiaries.
Discontinued operations, net of income taxes
Our discontinued operations include results of our discontinued FMC Lithium segment, in periods up to its separation on March 1, 2019, as well as adjustments to retained liabilities from other previously discontinued operations. The primary liabilities retained include environmental liabilities, other postretirement benefit liabilities, stock compensation, self-insurance, long-term obligations related to legal proceedings and historical restructuring activities.
Three Months Ended March 31, 2020 vs. 2019
Discontinued operations, net of income taxes representing a loss of $7.5 million for the three months ended March 31, 2020 decreased compared to income of $9.6 million for the three months ended March 31, 2019. The loss during the first quarter of 2020 was primarily related to adjustments related to the retained liabilities from our previously discontinued operations. During the three months ended March 31, 2019, we finalized the sale of the first of two parcels of land of our discontinued site in Newark, California and recorded a gain of approximately $21 million, net of tax. The gain on sale was partially offset by results of our discontinued FMC Lithium segment, which was a net loss due to separation-related costs, as well as charges from other previously discontinued operations. These events did not recur in the current period. Refer to Note 12 to the condensed consolidated financial statements included within this Form 10-Q for further information.
Net income (loss)
Three Months Ended March 31, 2020 vs. 2019
Net income (loss) decreased to $206.2 million from income of $217.2 million in the prior year period. The decrease was driven by the gain on sale of the parcel of land in Newark, California in the prior year period which was recorded in Discontinued operations, net of income taxes as discussed above. Partially offsetting the decrease were higher results from continuing operations as discussed in the sections above.
LIQUIDITY AND CAPITAL RESOURCES
Cash and cash equivalents at March 31, 2020 and December 31, 2019, were $436.2 million and $339.1 million, respectively. Of the cash and cash equivalents balance at March 31, 2020, $146.9 million were held by our foreign subsidiaries. The cash held by foreign subsidiaries for permanent reinvestment is generally used to finance the subsidiaries’ operating activities and future foreign investments. We have not provided income taxes for other additional outside basis differences inherent in our investments in subsidiaries because the investments are essentially permanent in duration or we have concluded that no additional tax liability will arise upon disposal or remittance. Determining the amount of unrecognized deferred tax liability related to permanent undistributed foreign earnings is not practicable due to the complexity of the hypothetical calculation.
At March 31, 2020, we had total debt of $3,782.0 million as compared to $3,258.8 million at December 31, 2019. Total debt included $3,531.8 million and $3,031.1 million of long-term debt (excluding current portions of $63.9 million and $82.8 million) at March 31, 2020 and December 31, 2019, respectively. The increase in long-term debt was driven by our revolver borrowings used to fund normal first quarter working capital build. We have historically relied on commercial paper to finance working capital. However, as COVID-19 became a more clear crisis in the U.S. in the middle of March, out of an abundance of caution, we elected to draw down approximately $500 million on the Revolving Credit Facility to ensure we had sufficient liquidity. Separately, we amended the Revolving Credit Facility and 2017 Term Loan Agreements to increase the maximum leverage ratio, also out of an abundance of caution. We do not have any liquidity issues, nor do we foresee any, and took this as a prudent step, as the higher leverage ratio provides significant headroom above any of the COVID-19 related scenarios assessed by the company. At March 31, 2020, our remaining borrowing capacity under our credit facility was $784.9 million.
As of March 31, 2020, we were in compliance with all of our debt covenants. See Note 11 in the condensed consolidated financial statements included in this Form 10-Q for further details. We remain committed to solid investment grade credit metrics, and expect full-year average leverage to be in line with this commitment in 2020.
Short-term debt, which consists of short-term foreign borrowings, increased from $227.7 million at December 31, 2019 to $250.2 million at March 31, 2020. We provide parent-company guarantees to lending institutions providing credit to our foreign subsidiaries.
Our commercial paper program allows us to borrow at rates generally more favorable than those available under our credit facility. At March 31, 2020, we had no borrowings under the commercial paper program.
Revolving Credit Facility and 2017 Term Loan Agreement Amendments
On April 22, 2020, we amended both our Revolving Credit Agreement and 2017 Term Loan Agreement which, among other things, increased the maximum leverage ratio financial covenant and added a negative covenant restricting purchases of the Company’s stock if at any time the maximum leverage ratio exceeds 3.5 through the period ending June 30, 2021. See Note 11 for further details.
Statement of Cash Flows
Cash provided (required) by operating activities of continuing operations was $(308.9) million and $(282.9) million for the three months ended March 31, 2020 and 2019, respectively.
The table below presents the components of net cash provided (required) by operating activities of continuing operations. For comparability, the prior period amounts for "Change in all other operating assets and liabilities" have been recast to reflect the current period presentation.
(in Millions)
| 2020 | Three Months Ended March 31, 2019 | |
|---|---|---|
| Income from continuing operations before non-operating pension and postretirement charges (income), interest expense, net and income taxes | $291.4 | $281.8 |
| Restructuring and other charges (income), transaction-related charges and depreciation and amortization | 65.5 | 61.6 |
| Operating income before depreciation and amortization (Non-GAAP) | $356.9 | $343.4 |
| Change in trade receivables, net (1) | (283.8) | (389.4) |
| Change in guarantees of vendor financing | (11.4) | 11.3 |
| Change in advance payments from customers (2) | (279.6) | (175.3) |
| Change in accrued customer rebates (3) | 102.2 | 95.0 |
| Change in inventories (4) | (63.3) | (109.7) |
| Change in accounts payable (5) | (68.1) | 91.0 |
| Change in all other operating assets and liabilities (6) | 8.6 | (48.5) |
| Operating cash flows (Non-GAAP) | $(238.5) | $(182.2) |
| Restructuring and other spending (7) | $(1.9) | $(5.8) |
| Environmental spending, continuing, net of recoveries (8) | 16.3 | (3.5) |
| Pension and other postretirement benefit contributions (9) | (1.2) | (1.6) |
| Net interest payments (10) | (32.1) | (35.8) |
| Tax payments, net of refunds (10) | (29.0) | (34.1) |
| Transactional-related legal and professional fees (11) | (22.5) | (19.9) |
| Cash provided (required) by operating activities of continuing operations | $(308.9) | $(282.9) |
(1) Both periods include the impacts of seasonality and the receivable build intrinsic in our business. The change in cash flows related to trade receivables in 2020 was driven by timing of collections. Collection timing is more pronounced in certain countries such as Brazil where there may be terms significantly longer than the rest of our business. Additionally, timing of collection is impacted as amounts for both periods include carry-over balances remaining to be collected in Latin America, where collection periods are measured in months rather than weeks. During the three months ended March 31, 2020, we collected approximately $161 million of receivables in Brazil.
(2) Advance payments are primarily associated within North America and these payments are received in the fourth quarter of each year and recorded as deferred revenue on the balance sheet at December 31. Revenue associated with advance payments is recognized, generally in the first half of each year, as shipments are made and control to the customer takes place. In 2020, customers chose to use higher amounts of prepaids against their first quarter 2020 purchases versus the year before.
(3) These rebates are primarily associated within North America, and to a lesser extent Brazil, and in North America generally settle in the fourth quarter of each year given the end of the respective crop cycle. The changes year over year are associated with the mix in sales eligible for rebates and incentives in 2020 compared to 2019 and timing of certain rebate payments.
(4) Changes in inventory are a result of inventory levels being adjusted to take into consideration the change in market conditions.
(5) The change in cash flows related to accounts payable is primarily due to the absence of payables in the prior year related to the delayed site transfer activity, as well as timing of payments made to suppliers and vendors.
(6) Changes in all periods presented primarily represent timing of payments associated with all other operating assets and liabilities. Additionally, both periods include the effects of the unfavorable contracts amortization of approximately $33 million and $27 million, respectively.
(7) See Note 10 in our condensed consolidated financial statements included in this Form 10-Q for further details.
(8) The amounts represent environmental remediation spending at our operating sites which were recorded against pre-existing reserves, net of recoveries. During the first quarter of 2020, we entered into a confidential insurance settlement pertaining to coverage at a legacy environmental site, which settlement resulted in a cash payment to FMC in the amount of $20.0 million. Refer to Note 13 for more details.
(9) There were no voluntary contributions to our U.S. qualified defined benefit plan for the three months ended March 31, 2020 and 2019.
(10) Amounts shown in the chart represent net payments of our continuing operations.
(11) Represents payments for legal and professional fees associated with the DuPont Crop Protection Business Acquisition in addition to costs related to integrating the DuPont Crop Protection Business. See Note 5 to the condensed consolidated financial statements included in this Form 10-Q for more information.
Cash provided (required) by operating activities of discontinued operations was $(19.4) million and $5.7 million for the three months ended March 31, 2020 and 2019, respectively.
Cash provided (required) by operating activities of discontinued operations is directly related to environmental, other postretirement benefit liabilities, stock compensation, self-insurance, long-term obligations related to legal proceedings and historical restructuring activities. 2019 includes the operating activities related to our discontinued FMC Lithium segment which accounts for the difference period over period.
Cash provided (required) by investing activities of continuing operations was $(43.2) million and $(33.4) million for the three months ended March 31, 2020 and 2019, respectively.
The change in cash from investing activities of continuing operations during the three months ended March 31, 2020, as compared to the same period in 2019, was primarily due to higher capitalizable corporate level spending associated with the implementation of a new SAP system and spending associated with contract manufacturers, partially offset by lower capital expenditure spending.
Cash provided (required) by investing activities of discontinued operations was zero and $9.2 million for the three months ended March 31, 2020 and 2019, respectively.
Cash provided by investing activities of discontinued operations for the three months ended March 31, 2019 represents the proceeds from the sale of the first of two parcels of land of our discontinued site in Newark, California partially offset by capital expenditures of our discontinued FMC Lithium segment.
Cash provided (required) by financing activities of continuing operations was $474.8 million and $287.6 million for the three months ended March 31, 2020 and 2019, respectively.
The change period over period in financing activities of continuing operations is primarily due to the lack of repurchases of common stock under our publicly announced program in 2020 versus $100 million in the prior period. Debt borrowings accounted for the majority of the remaining difference.
Cash provided (required) by financing activities of discontinued operations was zero and $(37.2) million for the three months ended March 31, 2020 and 2019, respectively.
Cash required by financing activities of discontinued operations for the three months ended March 31, 2019 represents debt repayments on FMC Lithium's external debt as well as cash payments associated with the separation of FMC Lithium.
Free Cash Flow
We define free cash flow, a Non-GAAP financial measure, as all cash inflows and outflows excluding those related to financing activities (such as debt repayments, dividends, and share repurchases) and acquisition related investing activities. Free cash flow is calculated as all cash from operating activities reduced by spending for capital additions and other investing activities as well as legacy and transformation spending. Therefore, our calculation of free cash flow will almost always result in a lower amount than cash from operating activities from continuing operations, the most directly comparable U.S. GAAP measure. However, the free cash flow measure is consistent with management's assessment of operating cash flow performance and we believe it provides a useful basis for investors and securities analysts about the cash generated by routine business operations, including capital expenditures, in addition to assessing our ability to repay debt, fund acquisitions and return capital to shareholders through share repurchases and dividends.
Our use of free cash flow has limitations as an analytical tool and should not be considered in isolation or as a substitute for an analysis of our results under U.S. GAAP. First, free cash flow is not a substitute for cash provided (required) by operating activities of continuing operations, as it is not a measure of cash available for discretionary expenditures since we have non-discretionary obligations, primarily debt service, that are not deducted from the measure. Second, other companies may calculate free cash flow or similarly titled Non-GAAP financial measures differently or may use other measures to evaluate their performance, all of which could reduce the usefulness of free cash flow as a tool for comparison. Additionally, the utility of free cash flow is further limited as it does not reflect our future contractual commitments and does not represent the total increase or decrease in our cash balance for a given period. Because of these and other limitations, free cash flow should be considered along with cash provided (required) by operating activities of continuing operations and other comparable financial measures prepared and presented in accordance with U.S. GAAP.
The table below presents a reconciliation of free cash flow from the most directly comparable U.S. GAAP measure:
FREE CASH FLOW RECONCILIATION
(in Millions)
| 2020 | Three Months Ended March 31, 2019 | |
|---|---|---|
| Cash provided (required) by operating activities of continuing operations (GAAP) | $(308.9) | $(282.9) |
| Transaction and integration costs (1) | 22.5 | 19.9 |
| Adjusted cash from operations (2) | $(286.4) | $(263.0) |
| Capital expenditures (3) | (15.5) | (19.1) |
| Other investing activities (3)(4) | (9.1) | (1.7) |
| Capital additions and other investing activities | $(24.6) | $(20.8) |
| Cash provided (required) by operating activities of discontinued operations (5) | (19.4) | 5.7 |
| Cash provided (required) by investing activities of discontinued operations (5) | — | 9.2 |
| Transaction and integration costs (1) | (22.5) | (19.9) |
| Investment in Enterprise Resource Planning system (3) | (18.6) | (12.6) |
| Legacy and transformation (6) | $(60.5) | $(17.6) |
| Free cash flow (Non-GAAP) | $(371.5) | $(301.4) |
(1) Represents payments for legal and professional fees associated with the DuPont Crop Protection Business Acquisition in addition to costs related to integrating the DuPont Crop Protection Business. See Note 5 to the condensed consolidated financial statements for more information.
(2) Adjusted cash from operations is defined as cash provided (required) by operating activities of continuing operations excluding the effects of transaction-related cash flows, which are included within Legacy and transformation.
(3) Components of cash provided (required) by investing activities of continuing operations. Refer to the below discussion for further details.
(4) Cash spending associated with contract manufacturers was $1.1 million and $0.1 million for the three months ended March 31, 2020 and 2019, respectively.
(5) Refer to the above discussion for further details.
(6) Includes our legacy liabilities such as environmental remediation and other legal matters that are reported in discontinued operations as well as business integration costs associated with the DuPont Crop Protection Business Acquisition and the implementation of our new SAP system.
2020 Cash Flow Outlook
Our cash needs for 2020 include operating cash requirements (which are impacted by potential contributions to our pension plan, as well as environmental, asset retirement obligation, and restructuring spending), capital expenditures, and legacy and transformation spending, as well as mandatory payments of debt, dividend payments, and share repurchases. We plan to meet our liquidity needs through available cash, cash generated from operations, commercial paper issuances and borrowings under our committed revolving credit facility. At March 31, 2020, our remaining borrowing capacity under our credit facility was $784.9 million.
We expect 2020 free cash flow (Non-GAAP) to increase to a range of approximately $425 million to $525 million, primarily driven by higher cash from operating activities. We continue to believe we can drive free cash conversion substantially higher over the next two to three years as we finalize our SAP system implementation, ending the three-year period of high cash spending on transformation activity and as we drive further improvement in working capital performance and continue to increase revenue and Adjusted EBITDA. While there is increased uncertainty in the global business environment, we are also taking several prudent steps to reduce cash outflows in 2020, such as deferring all discretionary capital investment and aggressively managing the balance of collections and payables to protect our cash position. Additionally, out of an abundance of caution given the current environment, we are temporarily suspending share repurchases until such time as we have more clear line of sight to a normalization of COVID-19 related disruptions.
Although we provide a forecast for free cash flow, a Non-GAAP financial measure, we are not able to forecast the most directly comparable measure calculated and presented in accordance with U.S. GAAP, which is cash provided (required) by operating activities of continuing operations. Certain elements of the composition of the U.S. GAAP amount are not predictable, making it impractical for us to forecast. Such elements include, but are not limited to, restructuring, acquisition charges, and discontinued operations. As a result, no U.S. GAAP outlook is provided.
Cash from operating activities of continuing operations
We expect higher cash from operating activities, excluding the effects of transaction-related cash flows, primarily driven by higher forecasted Adjusted EBITDA as well as continued improvement in working capital, to be in the range of approximately $700 million to $900 million. Transaction-related cash flows are included within Legacy and transformation, which is consistent with how we evaluate our business operations from a cash flow standpoint. See below for further discussion. Cash from operating activities includes cash requirements related to our pension plans, environmental sites, restructuring and asset retirement obligations, taxes, and interest on borrowings.
Pension
We do not expect to make any voluntary cash contributions to our U.S. qualified defined benefit pension plan in 2020. The plan is fully funded and our portfolio is comprised of 100 percent fixed income securities and cash. Our investment strategy is a liability hedging approach with an objective of maintaining the funded status of the plan such that the funded status volatility is minimized and the likelihood that we will be required to make significant contributions to the plan is limited.
Environmental
Projected 2020 spending, net of recoveries includes approximately $27 million to $37 million of net environmental remediation spending for our sites accounted for within continuing operations. Environmental obligations for continuing operations primarily represent obligations at shut down or abandoned facilities within businesses that do not meet the criteria for presentation as discontinued operations. This spending includes approximately $18 million related to our environmental remediation site near Pocatello, Idaho, primarily as a result of a litigation judgment against us in the Pocatello Tribal litigation. In addition to the expected 2020 payments for Pocatello, the judgment resulted in the requirement for future payments of $1.5 million annually thereafter. See Note 13 for further details.
Total projected 2020 environmental spending, inclusive of sites accounted for within both continuing operations and discontinued sites (discussed within Legacy and transformation below), is expected to be in the range of $82 million to $92 million.
Restructuring and asset retirement obligations
We expect to make payments of approximately $15 million to $25 million in 2020, of which approximately $6 million is related to exit and disposal costs as a result of our decision to exit sales of all carbofuran formulations (including Furadan® insecticide/nematicide, as well as Curaterr® insecticide/nematicide and any other brands used with carbofuran products) in 2019.
Capital additions and other investing activities
Projected 2020 capital expenditures and expenditures related to contract manufacturers are expected to be in the range of approximately $100 million to $150 million. The spending is primarily driven by diamide capacity expansion and new active ingredient capacity. Expenditures related to contract manufacturers are included within "Other investing activities".
Legacy and transformation
Projected 2020 legacy and transformation spending are expected to be in the range of approximately $175 million to $225 million. This is primarily driven by continued spending associated with the three-year implementation of a new SAP system and related costs we expect to continue to incur associated with the remaining integration of the DuPont Crop Protection Business due to its significance and complexity. Total spending related to these initiatives is expected to be approximately $125 million. Costs for these initiatives are expected to be immaterial beyond 2020.
Projected 2020 spending, net of recoveries includes approximately $50 million to $60 million of net environmental remediation spending for our discontinued sites. These projections include spending as a result of a settlement reached in 2019 at our Middleport, New York site. The settlement will result in spending of approximately $20 million to $30 million per year for 2020 and 2021, due to front loading of reimbursement in installments of past costs, and a $10 million maximum per year, on average, until the remediation is complete.
Total projected 2020 environmental spending, inclusive of sites accounted for within both continuing operations (discussed within Cash from operating activities of continuing operations above) and discontinued sites, is expected to be in the range of $82 million to $92 million.
Share repurchases
During the three months ended March 31, 2020, zero shares were repurchased under the publicly announced repurchase program. At March 31, 2020, approximately $600 million remained unused under our Board-authorized repurchase program. This repurchase program does not include a specific timetable or price targets and may be suspended or terminated at any time. Shares may be purchased through open market or privately negotiated transactions at the discretion of management based on its evaluation of market conditions and other factors. We also reacquire shares from time to time from employees in connection with the vesting, exercise and forfeiture of awards under our equity compensation plans.
As noted above, we are suspending share repurchases until we have a more clear line of sight to a normalization of COVID-19 related disruptions.
Dividends
During the three months ended March 31, 2020 and March 31, 2019, we paid dividends of $57.0 million and $53.2 million, respectively. On April 16, 2020, we paid dividends totaling $57.1 million to our shareholders of record as of March 31, 2020. We expect to continue to make quarterly dividend payments. Future cash dividends, as always, will depend on a variety of factors, including earnings, capital requirements, financial condition, general economic conditions and other factors considered relevant by us and is subject to final determination by our Board of Directors. On April 28, 2020, the Board of Directors declared a regular quarterly dividend of 44 cents per share, payable on July 16, 2020, to shareholders of record as of the close of business on June 30, 2020.
Commitments and Contingencies
See Note 19 to the condensed consolidated financial statements included in this Form 10-Q.
Contractual Commitments
Information related to our contractual commitments at December 31, 2019 can be found in a table included within Part II, Item 7 of our 2019 Form 10-K. There have been no significant changes to our contractual commitments during the three months ended March 31, 2020.
Climate Change
A detailed discussion related to climate change can be found in Part II, Item 7 of our 2019 Form 10-K.
Off-Balance Sheet Arrangements
We do not have any off-balance sheet arrangements that have or are reasonably likely to have a current or future effect on our financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources that is material to investors.
Fair Value Measurements
See Note 18 to the condensed consolidated financial statements in this Form 10-Q for additional discussion surrounding our fair value measurements.
DERIVATIVE FINANCIAL INSTRUMENTS AND MARKET RISKS
Our earnings, cash flows, and financial position are exposed to market risks relating to fluctuations in commodity prices, interest rates, and foreign currency exchange rates. Our policy is to minimize exposure to our cash flow over time caused by changes in commodity, interest, and currency exchange rates. To accomplish this, we have implemented a controlled program of risk management consisting of appropriate derivative contracts entered into with major financial institutions.
The analysis below presents the sensitivity of the market value of our financial instruments to selected changes in market rates and prices. The range of changes chosen reflects our view of changes that are reasonably possible over a one-year period. Market-value estimates are based on the present value of projected future cash flows considering the market rates and prices chosen.
At March 31, 2020, our financial instrument position was a net asset of $41.2 million compared to a net liability of $8.9 million at December 31, 2019. The change in the net financial instrument position was primarily due to changes in foreign exchange and interest rates.
Since our risk management programs are generally highly effective, the potential loss in value for each risk management portfolio described below would be largely offset by changes in the value of the underlying exposure.
Commodity Price Risk
Energy costs are diversified among electricity and natural gas. We attempt to mitigate our exposure to increasing energy costs by hedging the cost of future deliveries of natural gas and electricity. To analyze the effect of changing energy prices, we perform a sensitivity analysis in which we assume an instantaneous 10 percent change in energy market prices from their levels at March 31, 2020 and December 31, 2019, with all other variables (including interest rates) held constant. Note, as of March 31, 2020 and December 31, 2019, we had no open commodity contracts. As a result, there was no sensitivity analysis performed over commodity price risk for the periods presented.
Foreign Currency Exchange Rate Risk
The primary currencies for which we have exchange rate exposure are the U.S. dollar versus the Euro, the Chinese yuan, the Brazilian real, Mexican peso, and the Argentine peso. Foreign currency debt and foreign exchange forward contracts are used in countries where we do business, thereby reducing our net asset exposure. Foreign exchange forward contracts are also used to hedge firm and highly anticipated foreign currency cash flows.
To analyze the effects of changing foreign currency rates, we have performed a sensitivity analysis in which we assume an instantaneous 10 percent change in the foreign currency exchange rates from their levels at March 31, 2020 and December 31, 2019, with all other variables (including interest rates) held constant.
(in Millions)
| Net Asset / (Liability) Position on Condensed Consolidated Balance Sheets | 10% Strengthening | 10% Weakening | |
|---|---|---|---|
| Net asset (liability) position at March 31, 2020 | $46.5 | $88.2 | $3.8 |
| Net asset (liability) position at December 31, 2019 | (8.0) | 55.9 | (75.4) |
Interest Rate Risk
One of the strategies that we can use to manage interest rate exposure is to enter into interest rate swap agreements. In these agreements, we agree to exchange, at specified intervals, the difference between fixed and variable interest amounts calculated on an agreed-upon notional principal amount. As of March 31, 2020, we had outstanding interest rate swap contracts in place with an aggregate notional value of $300.0 million.
To analyze the effects of changing interest rates, we have performed a sensitivity analysis in which we assume an instantaneous one percent change in the interest rates from their levels at March 31, 2020 and December 31, 2019, with all other variables held constant.
(in Millions)
| Net Asset / (Liability) Position on Condensed Consolidated Balance Sheets | 1% Increase | 1% Decrease | |
|---|---|---|---|
| Net asset (liability) position at March 31, 2020 | $(5.3) | $4.5 | $(16.7) |
| Net asset (liability) position at December 31, 2019 | (0.9) | — | (1.9) |
Our debt portfolio, at March 31, 2020, is composed of 67 percent fixed-rate debt and 33 percent variable-rate debt. The variable-rate component of our debt portfolio principally consists of borrowings under our 2017 Term Loan Facility, Revolving Credit Facility, commercial paper program, variable-rate industrial and pollution control revenue bonds, and amounts outstanding under foreign subsidiary credit lines. Changes in interest rates affect different portions of our variable-rate debt portfolio in different ways.
Based on the variable-rate debt in our debt portfolio at March 31, 2020, a one percentage point increase in interest rates then in effect would have increased gross interest expense by $3.1 million and a one percentage point decrease in interest rates then in effect would have decreased gross interest expense by $2.8 million for the three months ended March 31, 2020.
Market risk
As filed, 207 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.
The information required by this item is provided in "Derivative Financial Instruments and Market Risks," under ITEM 2 - Management’s Discussion and Analysis of Financial Condition and Results of Operations.
Controls and procedures
As filed, 4,451 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.
(a) Evaluation of disclosure controls and procedures. Based on management’s evaluation (with the participation of the Company’s Chief Executive Officer and Chief Financial Officer), the Chief Executive Officer and Chief Financial Officer have concluded that, as of March 31, 2020, the Company’s disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934) are effective to provide reasonable assurance that information required to be disclosed by the Company in reports filed or submitted under the Securities Exchange Act of 1934 is recorded, processed, summarized and reported within the time periods specified in the Securities and Exchange Commission’s rules and forms and is accumulated and communicated to management, including our principal executive officer and principal financial officer, as appropriate to allow timely decisions regarding required disclosure.
(b) Change in Internal Controls. During the first quarter of 2020, we completed another phase of our ERP implementation by migrating the acquired entities of the DuPont Crop Protection Business to the new system and exiting the transitional services agreement. As a result, we have implemented updates and changes to our current processes and related control activities. As the phased implementation continues, we will experience certain changes to our processes and procedures which, in turn, will result in changes to our internal controls over financial reporting. For a discussion of risks related to the implementation of new systems, see Part I, Item 1A "Risk Factors" of our 2019 Form 10-K.
Other than as stated above in this paragraph, there have been no changes in internal controls over financial reporting that occurred during the quarter ended March 31, 2020 that materially affected or are reasonably likely to materially affect our internal controls over financing reporting.
Report of Independent Registered Public Accounting Firm
To the Stockholders and Board of Directors
FMC Corporation:
Results of Review of Interim Financial Information
We have reviewed the condensed consolidated balance sheet of FMC Corporation and subsidiaries (the Company) as of March 31, 2020, the related condensed consolidated statements of income (loss), comprehensive income (loss), changes in equity, and cash flows for the three-month periods ended March 31, 2020 and 2019, and the related notes (collectively, the consolidated interim financial information). Based on our reviews, we are not aware of any material modifications that should be made to the consolidated interim financial information for it to be in conformity with U.S. generally accepted accounting principles.
We have previously audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the consolidated balance sheet of the Company as of December 31, 2019, and the related consolidated statements of income (loss), comprehensive income (loss), changes in equity, and cash flows for the year then ended (not presented herein); and in our report dated February 28, 2020, we expressed an unqualified opinion on those consolidated financial statements. In our opinion, the information set forth in the accompanying condensed consolidated balance sheet as of December 31, 2019, is fairly stated, in all material respects, in relation to the consolidated balance sheet from which it has been derived.
Basis for Review Results
This consolidated interim financial information is the responsibility of the Company’s management. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.
We conducted our reviews in accordance with the standards of the PCAOB. A review of consolidated interim financial information consists principally of applying analytical procedures and making inquiries of persons responsible for financial and accounting matters. It is substantially less in scope than an audit conducted in accordance with the standards of the PCAOB, the objective of which is the expression of an opinion regarding the financial statements taken as a whole. Accordingly, we do not express such an opinion.
/s/ KPMG LLP
Philadelphia, Pennsylvania
May 6, 2020
Risk factors
As filed, 3,349 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.
In December 2019, the 2019 novel coronavirus surfaced in Wuhan, China. In January 2020, this coronavirus spread to other countries, and efforts to contain the spread of this coronavirus intensified. The full and longer-term impacts of the outbreak are unknown and rapidly evolving. This outbreak may impact access to our production sites or to adequately and safely staff our production sites, the ability of raw material suppliers to produce and deliver goods to us, our ability to ship our products to production, warehousing or customer sites, or the ability of our sales organization to make sales or for customers (or indirect customers such as farmers) to purchase our products. Our supply chain and business operations could be disrupted from the temporary closure of third-party supplier and manufacturer facilities, interruptions in product supply or restrictions on the export or shipment of our products. Any disruption of our suppliers and contract manufacturers could impact our sales and operating results. The outbreak, and governmental responses to the outbreak, have caused disruption in certain food distribution systems and labor markets for planting and harvesting, which in turn have created operational and financial pressures on some farmers who are the ultimate users of the vast majority of our products. If those pressures continue and grow more widespread or severe, and if farmers materially change their planting decisions or choose not to protect their crops with our products, such pressures on farmers could impact our sales and operating results. Global health concerns, such as coronavirus, could also result in social, economic, and labor instability in the countries in which we or our customers and suppliers operate. These uncertainties could have a material adverse effect on our business and our results of operation and financial condition. A widespread health crisis could adversely affect the global economy, resulting in an economic downturn that could impact demand for our products. Although our production operations that support agriculture have generally been viewed as "essential" and exempted from governmental lockdown orders, the future impact of the outbreak is highly uncertain and cannot be predicted and there is no assurance that the outbreak will not have a material adverse impact on the future results of the Company. The extent of the impact, if any, will depend on future developments, including actions taken to contain the coronavirus.
In addition to the other information set forth in this Form 10-Q, you should carefully consider the factors discussed in Part I, Item 1A "Risk Factors" of our 2019 Form 10-K filed with the U.S. Securities and Exchange Commission (the "SEC") for the fiscal year ended December 31, 2019 and the Company’s other filings with the SEC, which are available at www.sec.gov (http://www.sec.gov) and on the Company’s website at www.fmc.com (http://www.fmc.com).
Forward-Looking Information
We wish to caution readers not to place undue reliance on any forward-looking statements contained herein, which speak only as of the date made. We specifically decline to undertake any obligation to publicly revise any forward-looking statements that have been made to reflect events or circumstances after the date of such statements or to reflect the occurrence of anticipated or unanticipated events.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2020-03-31. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 3 months2020-01-01 to 2020-03-31 | $1.25bn | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Cost of revenue | 3 months2020-01-01 to 2020-03-31 | $688.5m | us-gaap:CostOfRevenue |
| Gross profit | 3 months2020-01-01 to 2020-03-31 | $561.5m | us-gaap:GrossProfit |
| Selling, general and administrative | 3 months2020-01-01 to 2020-03-31 | $189.4m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Operating income | 3 months2020-01-01 to 2020-03-31 | $291.4m | us-gaap:OperatingIncomeLoss |
| Income tax | 3 months2020-01-01 to 2020-03-31 | $34.7m | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months2020-01-01 to 2020-03-31 | $206.2m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months2020-01-01 to 2020-03-31 | $1.58 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months2020-01-01 to 2020-03-31 | $1.59 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months2020-01-01 to 2020-03-31 | 130,466,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 3 months2020-01-01 to 2020-03-31 | −$308.9m | us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations |
| Capital expenditure | 3 months2020-01-01 to 2020-03-31 | $15.5m | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Dividends paid | 3 months2020-01-01 to 2020-03-31 | $57.0m | us-gaap:PaymentsOfDividendsCommonStock |
| Share repurchases | 3 months2020-01-01 to 2020-03-31 | $0 | us-gaap:PaymentsForRepurchaseOfCommonStock |
| Cash and equivalents | At period end2020-03-31 | $436.2m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2020-03-31 | $4.47bn | us-gaap:AssetsCurrent |
| Total assets | At period end2020-03-31 | $10.19bn | us-gaap:Assets |
| Current liabilities | At period end2020-03-31 | $2.46bn | us-gaap:LiabilitiesCurrent |
| Long-term debt | At period end2020-03-31 | $3.53bn | us-gaap:LongTermDebtNoncurrent |
| Current portion of debt | At period end2020-03-31 | $63.9m | us-gaap:LongTermDebtCurrent |
| Short-term borrowings | At period end2020-03-31 | $186.3m | us-gaap:ShortTermBorrowings |
| Shareholders' equity | At period end2020-03-31 | $2.68bn | us-gaap:StockholdersEquity |
| Shares outstanding | At period end2020-03-31 | 129,447,184 shares | dei:EntityCommonStockSharesOutstanding |
Source: SEC EDGAR, the filing index for accession 0000037785-20-000079. Last ingested by Listed: Nov 13, 2026, 16:31 ET. Listed shows no prices and gives no investment advice.